Condition: Hematologic Malignancies · Sponsor: Sellas Life Sciences Group
SLS009 (formerly GFH009) is a potent and highly selective CDK9 inhibitor. In this study the safety, tolerability, and antitumor activity of single agent SLS009 are assessed in two dose escalation groups (Group 1 in patients with relapsed/refractory AML, Group 2 in patients with relapse/refractory lymphoma/CLL/SLL). The safety, tolerability, and antitumor activity of SLS009 in combination with venetoclax and azacitidine in patient with relapsed/refractory AML who have relapsed on or are refractory to venetoclax-based regimens are being assessed in five cohorts of the expansion Group 3. Groups 4 and 5 have been added to evaluate efficacy, safety, and tolerability of GFH009 in combination with venetoclax and azacitidine in newly diagnosed AML patients who are less likely to benefit from standard induction treatment with venetoclax plus HMA only regimens.
This description comes directly from the study's public registry record.
James Dean · +1 609-656-3564 · jdean@sellaslife.com
Clinical Trials Info at Sellas · +1 646-200-5278 · clinicaltrialinfo@sellaslife.com
Always discuss trial participation with your own doctor first.
| O'Neal Comprehensive Cancer Center, University of Alabama | Birmingham, Alabama, United States | Recruiting |
| City of Hope - Phoenix | Goodyear, Arizona, United States | Recruiting |
| City of Hope National Medical Center | Duarte, California, United States | Recruiting |
| Moffitt Cancer Center | Tampa, Florida, United States | Recruiting |
| City of Hope - Atlanta | Newnan, Georgia, United States | Recruiting |
| City of Hope - Chicago | Zion, Illinois, United States | Recruiting |
| Ochsner Clinic Foundation | New Orleans, Louisiana, United States | Terminated |
| Clinical Research Alliance, Inc. | Lake Success, New York, United States | Terminated |
| New York - Presbyterian Hospital | New York, New York, United States | Terminated |
| UNC School of Medicine, Division of Hematology | Chapel Hill, North Carolina, United States | Recruiting |
| Bon Secours St. Francis Cancer Center | Greenville, South Carolina, United States | Recruiting |
| Baylor Scott & White Health | Dallas, Texas, United States | Recruiting |
+ 14 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04588922